At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Pembrolizumab with All-Trans Retinoic Aciddrug
Likely dose
Pembrolizumab with All-Trans Retinoic Acid 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab with All-Trans Retinoic Acid for Stage IV Melanoma and 2 related conditions. Completed, enrolled 26 participants across 2 sites.
Detailed Summary
This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Melanoma, Stage III Melanoma, Advanced Melanoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartOct 2017
Primary CompletionJul 2022
Study CompletionOct 2022
TodayJul 2026
First PostedJun 27, 2017
Enrollment StartOct 31, 2017
Primary CompletionJul 20, 2022
Study CompletionOct 19, 2022
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.0 years ago
Interventions
Pembrolizumab with All-Trans Retinoic Aciddrug
All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab